<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T2" position="float">
 <label>Table 2</label>
 <caption>
  <p>Clinical trials employing DNA vaccines in pandemic settings.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Study start</bold>
    </th>
    <th valign="top" align="center" rowspan="1" colspan="1">
     <bold>
      <italic>N</italic>
     </bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Vaccine and delivery</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Outcome</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT00072605</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>EBOLA</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Oct 2003</td>
    <td valign="top" align="center" rowspan="1" colspan="1">27</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>DNA</bold>, trivalent; NF inj.dev. IM 2–8 mg in week 0, 4, and 8 Antigens: 
     <break/>- GPΔTM EBOV 
     <break/>- GPΔTM SUDV 
     <break/>- NP
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable safety profile 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/> - Specific antibody response to at least 1/3 antigens in all subjects 
     <break/>- Specific CD8
     <sup>+</sup> T cell responses in 30% (6/20) subjects. 
     <break/>- No detectable virus neutralizing responses
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT00605514</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>EBOLA</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Jan 2008</td>
    <td valign="top" align="center" rowspan="1" colspan="1">20</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>DNA</bold>, mono or bivalent; NF inj.dev. IM 4 mg in week 0, 4, 8; (32) Antigens: 
     <break/>- GP MARV 
     <break/>- GP EBOV + GP SUDV
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable safety profile 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/> - Specific antibody responses against one of the GPs at week 12 in 80% of subjects 
     <break/>- CD8
     <sup>+</sup> T cell responses in some of the subjects
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT00997607</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>EBOLA</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase Ib</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Feb 2010</td>
    <td valign="top" align="center" rowspan="1" colspan="1">108</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>DNA</bold>, mono or bivalent; NF inj.dev. IM 4 mg in week 0, 4, 8 Antigens: 
     <break/>- GP MARV 
     <break/>- GP EBOV + GP SUDV
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable safety profile 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/> Specific antibody responses in 30% (MARV) and 50% (EBOV or SUDV) of subjects Antibody titers to near baseline levels by w 44 post vaccination
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT02464670</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>EBOLA</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">May 2015</td>
    <td valign="top" align="center" rowspan="1" colspan="1">240</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>DNA</bold>, mono-, bi- or trivalent; IM or ID + EP in 2 or 3 doses 0.8–4 mg GP; 0.2–1 mg IL12 Antigen: 
     <break/>- GP EBOV pre 2013 
     <break/>- and/or GP EBOV 2014 
     <break/>- and IL-12 in trivalent vaccine
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable safety profile 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/> Specific antibody responses in 88% (50/57) (IM) and 95% (119/122) (ID) of participants
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT00709800 and NCT00694213</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>INFLUENZA H5N1</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Aug 2007</td>
    <td valign="top" align="center" rowspan="1" colspan="1">103</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>DNA</bold>, mono- or trivalent; needle or NF inj.dev. IM 0.1–1 mg in week 0, 3 Antigen: 
     <break/>- HA of A/Vietnam/1203/04 
     <break/>- HA + NP + M2
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable safety profile 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/> - HI titers ≥40, in 47- 67% (HA only) and 0- 20% (HA + NP + M2) of participants, peak at d56 
     <break/>- H5-specific T cell responses in 75–100% (HA only) and 50–57% % (HA + NP + M2) of subjects 
     <break/>- Responses against HA unaffected by injection method
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT00973895</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>INFLUENZA H1N1</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Aug 2009</td>
    <td valign="top" align="center" rowspan="1" colspan="1">20</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>DNA</bold>, monovalent; NF inj.dev. IM 4 mg in week 0, 4, 8 Antigen: HA of A/California/04/2009
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable safety profile 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/> - HI titers ≥40 in 30% (6/20) of DNA vaccinated subjects 
     <break/>- DNA + licensed vaccine HI titers ≥40 in 72% (13/18) 
     <break/>- T cell responses in 25% (5/20) of subjects
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT02809443 (NCT02887482)</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>ZIKA</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">July 2016 (Aug 2016)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">40 (160)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>DNA</bold>, monovalent; ID + EP 1 or 2 mg in week 0, 4, 12 Antigen: Consensus prM-E; IgE SP; removed glycosylation site
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable safety profile (NCT02809443) 
     <break/>
     <bold>Immunogenicity (preliminary results NCT02809443):</bold>
     <break/> - VNTs in 62% of the participants (Vero cell assay) 
     <break/>- Protection of 92% (103/112) of mice by passive serum transfer in challenge model (IFN α/β receptor knockout)
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT02840487; NCT02996461</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>ZIKA</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I/Ib</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Aug 2016 Dec 2016</td>
    <td valign="top" align="center" rowspan="1" colspan="1">125</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>DNA</bold>, monovalent; needle or NF inj.dev. IM 4 mg in 2 or 3 doses Antigen: 
     <break/>- prM-E; JEV SP (VRC5283) 
     <break/>- prM-E; JEV SP and S/TM (VRC5288)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable safety profile 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/> - Humoral and T cell responses induced 
     <break/>- VNTs in 60%−100% of subjects 4 w after the final vaccination 
     <break/>- Best responses in VRC5283: Antibody responses in 100% (14/14) of participants in NF inj, in split doses group; best VNT and T cell responses
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="2" rowspan="1">
     <bold>NCT03110770</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>ZIKA</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase II</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Mar 2017</td>
    <td valign="top" align="center" rowspan="1" colspan="1">2500</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>DNA</bold>, monovalent; NF inj.dev. IM in 3 doses 4 mg or 8 mg in 2 or 4 inj. Antigen: 
     <break/>- prM-E; JEV SP (VRC5283)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Results pending, estimated study completion date Jan 2020</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>This table exclusively lists clinical trials discussed in the text. EBOV, Ebola virus; EP, electroporation; GP, glycoprotein; GPΔTM, glycoprotein delta transmembrane domain; HA, hemagglutinin influenza; HI, hemagglutination inhibition; ID, intradermal; IL-12, interleukin 12; IM, intramuscular; JEV, Japanese encephalitis virus; M2, ion channel protein influenza; MARV, Marburg virus; N, number of study participants; NF inj.dev, needle free injection device; NP, nucleoprotein influenza; prM-E, preMembrane-Envelope; SUDV, Sudan virus; VNT, virus neutralization titer; SP, signal peptide; S/TM, stem and transmembrane regions</italic>.
  </p>
 </table-wrap-foot>
</table-wrap>
